Breast cancer is the most commonly diagnosed cancer in Chinese women. With a high incidence and prolonged treatment duration, breast cancer presents a lucrative commercial opportunity for drug manufacturers. Over the last few years, the drug-treatment rate for breast cancer in China has increased owing to the availability of novel, premium-priced, targeted therapies (e.g., pertuzumab [Roche’s Perjeta]) and the inclusion of these agents in the National Reimbursement Drug List. Based on the strong late-phase pipeline, we expect more new agents to launch for breast cancer in China during the forecast period. Additionally, in view of ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.